[1]陈 辰,张 帆,赵 琨,等.基于ACCE框架的遗传学检测技术评估框架研究[J].卫生经济研究,2020,(06):33-37.
　CHEN Chen,ZHANG Fan,ZHAO Kun,et al.Research on Evaluation Framework of Genetic Testing Technology Based on ACCE Framework[J].Journal Press of Health Economics Research,2020,(06):33-37.
点击复制

基于ACCE框架的遗传学检测技术评估框架研究
分享到：

卫生经济研究[ISSN:1004-7778/CN:33-1056/F]

卷:
期数:
2020年06期
页码:
33-37
栏目:
方法学应用
出版日期:
2020-06-04

文章信息/Info

Title:
Research on Evaluation Framework of Genetic Testing Technology Based on ACCE Framework
作者:
陈 辰1; 2; 张 帆2; 3; 赵 琨2; 3; 杨洪伟2; 3; 刘跃华2; 3
1.中国药科大学国际医药商学院，江苏 南京 211198
2.国家卫生健康委卫生发展研究中心，北京 100044
3.国家药物和卫生技术综合评估中心，北京 100044
Author(s):
CHEN Chen; ZHANG Fan; ZHAO Kun; YANG Hong-wei; LIU Yue-hua
College of International Pharmaceutical Business，China Pharmaceutical University, Nanjing Jiangsu 211198,China
关键词:
遗传学检测; 框架; 评估
Keywords:
genetic testing;  framework;  evaluation
分类号:
R19
文献标志码:
A
摘要:
采用文献研究法，梳理以ACCE模式为基础的遗传学检测技术评估框架，剖析不同评估框架的评估维度，建议构建我国遗传学检测技术评估框架：以ACCE框架的五大维度（疾病/临床背景，分析有效性，临床有效性，临床效用，伦理、社会及法律影响）为基础，进行发展和完善；针对不同的遗传学检测技术特点形成专用评估框架。
Abstract:
The literature research method was used to sort out the genetic testing technology evaluation framework based on the ACCE model, analyze the evaluation dimensions of different evaluation frameworks, and recommend the construction of genetic testing technology evaluation framework in China: using the five dimensions of the ACCE framework (including disease/clinical background, analysis of effectiveness, clinical effectiveness, clinical utility, ethical, social and legal impacts) as the basis for development and improvement; and forming the special evaluation framework for different genetic testing technology characteristics.

参考文献/References:

[1] National Research Council (US) Committee.Toward Precision Mdedicine:Building a Knowledge Network for Biomedical Research and a New Taxonomy of Disease[M].Washington DC:National Academies Press, 2011.
[2] Committee on the Evidence Base for Genetic Testing. An evidence framework for genetic testing[M]. Washington DC:The National Academies Press, 2017.
[3] 我国每年新发癌症病例超350万[EB/OL]. (2018-04-15)[ 2019-08-28].http://www.xinhuanet.com/2018-04/15/c_1122685318.htm.
[4] Public Health Genomics. ACCE Model List of 44 Targeted Questions[EB/OL]. (2010-12-28)[2019-08-28].https://www.cdc.gov/genomics/gtesting/acce/acce_proj.htm.
[5] Teutsch S M , Bradley L A , Palomaki G E , et al. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) initiative: methods of the EGAPP Working Group[J]. Genetics in Medicine, 2009, 11(1):3-14.
[6] Burke W , Zimmern R . Moving Beyond ACCE : An Expanded Framework for Genetic Test Evaluation[J]. PHG Foundation,2007.
[7] EuroGentest .Clinical utility gene cards [EB/OL]. [2019-08-28].http://www.eurogentest.org/index.php?id=668.
[8] Márquez Calderón S, Briones Pérez, de la Blanca E. Framework for the assessment of genetic testing in the Andalusian Public Health System. Seville, Andalusia: Andalusian Agency for Health Technology Assessment,2006.
[9] Mark K , Ron LZ, Peter F, et al.How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network[J].European Journal of Human Genetics,2007,15(9): 917-921.
[10] UK Genetic Testing Network . Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier/Additional Provider [EB/OL]. [2019-08-28].https://ukgtn.nhs.uk/fileadmin/uploads/ukgtn/Documents/Resources/Library/Policies_Procedures/Gene_ Dossier_Additional_Provider_Form_-_2017.doc.
[11] Calonge N , Green NS , Rinaldo P , et al. Committee report: Method for evaluating conditions nominated for population-based screening of newborns and children[J]. Genetics in Medicine, 2010, 12(3):153-159.
[12] Medical Services Advisory Committee. About MSAC [EB/OL]. (2016-06-29)[2019-08-28].https://www1.health.gov.au/internet/msac/publishing.nsf/Content/about-msac.
[13] Medical Services Advisory Committee.Clinical Utility Card for Heritable Mutations[EB/OL].[2019-08-28].https://www1.health.gov.au/internet/msac/publishing.nsf/Content/0BD63667C984FEE ACA25801000123AD8/$File/Glossary-CUC-proforma.docx.
[14] Zimmern RL, Kroese M. The evaluation of genetic tests[J]. Public Health,2007(29):246-250.
[15] Drummond MF, Sculpher MJ, Claxton K, Torrance GW, Stoddart GL, editors. Methods for the economic evaluation of health care programmes. 4th edn. Oxford, UK: Oxford University Press,2015.
[16] 基因谷.全国肿瘤体细胞突变高通量测序检测第一次室间质量评价满分单位 [EB/OL]. (2017-05-08)[ 2019-08-28] .http://www.sohu.com/a/139038550_733985.
[17] 国家卫健委、医保局共识：将卫生技术评估用于医保准入[EB/OL] .(2018-11-30)[2019-08-25].https://www.cn-healthcare.com/article/20181130/content-511652.html.

更新日期/Last Update: 2020-06-04